tetano
Editor, Senior Moderator
J Pediatr Nurs. 2012 Apr;27(2):163-7. Epub 2011 Jan 31.
Clinical guidance on the use of live attenuated influenza vaccine after inadvertent freezing and warming.
Toback SL, Susla GM, Darling AJ, Ambrose CS.
Abstract
The immediate and long-term impact of temperature deviations that may occur in clinical practice on live attenuated influenza vaccine (LAIV) potency was examined in four distinct studies that exposed vaccine to freeze/thaw cycles, warming, and heating conditions. No significant loss of vaccine potency was observed after three freeze/thaw cycles, warming of vaccine to 15?C (59?F) for 72 hours or less, exposure to room temperature (25?C/77?F) for 12 hours or less, or after heating to 37?C (99?F) for 6 hours or less. The results of these studies demonstrate that LAIV potency can potentially be maintained after exposure to temperature deviations. If a particular annual formulation of LAIV is exposed to temperatures outside of the recommended storage range, practitioners should contact the manufacturer for guidance regarding proper vaccine handling.
Copyright © 2012 Elsevier Inc. All rights reserved.
PMID:
22341195
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22341195
Clinical guidance on the use of live attenuated influenza vaccine after inadvertent freezing and warming.
Toback SL, Susla GM, Darling AJ, Ambrose CS.
Abstract
The immediate and long-term impact of temperature deviations that may occur in clinical practice on live attenuated influenza vaccine (LAIV) potency was examined in four distinct studies that exposed vaccine to freeze/thaw cycles, warming, and heating conditions. No significant loss of vaccine potency was observed after three freeze/thaw cycles, warming of vaccine to 15?C (59?F) for 72 hours or less, exposure to room temperature (25?C/77?F) for 12 hours or less, or after heating to 37?C (99?F) for 6 hours or less. The results of these studies demonstrate that LAIV potency can potentially be maintained after exposure to temperature deviations. If a particular annual formulation of LAIV is exposed to temperatures outside of the recommended storage range, practitioners should contact the manufacturer for guidance regarding proper vaccine handling.
Copyright © 2012 Elsevier Inc. All rights reserved.
PMID:
22341195
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22341195